Follow Us:
Monday, July 04, 2022

Adar Poonawala


Will give adequate security to SII CEO on return to India: Maharashtra to HC

June 12, 2021 10:55 am

Disposes of plea after state govt assurance that adequate security will be provided to SII CEO on his India return

Adar Poonawalla's Serum Institute to invest 240 million pounds in UK

May 04, 2021 10:56 am

The Pune-based vaccine manufacturer is among a list of nearly 20 Indian companies across sectors such as healthcare, biotech and software services to announce significant investment plans in the UK.

Serum Institute's Rs 600/dose for Covishield in private hospitals is its highest rate the world over

April 25, 2021 8:39 am

This, despite it being contract-manufactured by Pune’s Serum Institute of India whose CEO Adar Poonawalla had said that the firm was making a profit even at a price of Rs 150 per dose.

Adar Poonawalla gets vaccine shot: ‘my endorsement very important’

January 17, 2021 4:26 am

Poonawalla took to Twitter and posted a video which showed that he was injected with the vaccine

No safety concerns related to the Covishield vaccine trial: Serum chief

November 05, 2020 11:07 am

Adar Poonawalla, CEO of SII said preliminary results have shown that there are no immediate concerns pertaining to the Covishield vaccine. A total of 1600 people have been administered the first dose across 17 sites, and each participant is being followed up for six months to ensure safety of the vaccine.

Oxford's Covid-19 vaccine could be ready by December, says Serum Institute CEO

October 28, 2020 9:07 pm

"If we don't go for an emergency license, our trials should be over by December and then we can maybe we can launch in India in January subject to the UK trial, which is on the verge of being completed," Adar Poonawalla said.

Serum Institute CEO Adar Poonawala has a question for govt: 'Will it have Rs 80,000 cr to give each Indian Covid vaccine'

September 28, 2020 9:12 am

Serum Institute of India has the licence to produce and market two of the leading vaccine candidates, one being developed by AstraZeneca and the Oxford University, and the other one by US company Novavax.